DOCSLIB.ORG

IGFBP2 Is a Candidate Biomarker for Ink4a-Arf Status and a Therapeutic Target for High-Grade Gliomas

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IGFBP2 Is a Candidate Biomarker for Ink4a-Arf Status and a Therapeutic Target for High-Grade Gliomas IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas Lynette M. Moorea, Kristen M. Holmesa, Sarah M. Smitha, Ying Wua, Elena Tchougounovab, Lene Uhrbomb, Raymond Sawayac, Janet M. Brunera, Gregory N. Fullera,1, and Wei Zhanga,1 Departments of aPathology and cNeurosurgery, University of Texas MD Anderson Cancer Center, Houston, TX 77030; and bDepartment of Genetics and Pathology, Uppsala University, Rudbeck Laboratory, SE-751 85, Uppsala, Sweden Edited by Webster K. Cavenee, University of California at San Diego, La Jolla, CA, and approved August 14, 2009 (received for review January 23, 2009) The levels of insulin-like growth factor-binding protein 2 (IGFBP2) Genetic studies and genomic profiling of human gliomas have are elevated during progression of many human cancers. By using identified a number of common alterations, including frequent a glial-specific transgenic mouse system (RCAS/Ntv-a), we reported deletion of the INK4a-ARF locus, loss of PTEN, and overex- previously that IGFBP2 is an oncogenic factor for glioma progres- pression of IGFBP2, and these comprehensive studies have sion in combination with platelet-derived growth factor-␤ revealed valuable information regarding critical pathways used (PDGFB). Because the INK4a-ARF locus is often deleted in high- by gliomas (9, 10). IGFBP2 overexpression is correlated with grade gliomas (anaplastic oligodendroglioma and glioblastoma), high-grade gliomas and poor prognosis, and experiments from we investigated the effect of the Ink4a-Arf-null background on our laboratory have demonstrated that IGFBP2 is an oncogene IGFBP2-mediated progression of PDGFB-initiated oligodendrogli- that promotes glioma development and progression in a glial- oma. We demonstrate here that homozygous deletion of Ink4a-Arf specific mouse model (11–13). Further, IGFBP2 and PTEN ex- bypasses the requirement of exogenously introduced IGFBP2 for pression levels are negatively correlated in brain and prostate glioma progression. Instead, absence of Ink4a-Arf resulted in cancers, implicating IGFBP2 as a biomarker for PTEN status (14). elevated endogenous tumor cell IGFBP2. An inverse relationship In addition to PTEN, loss of Ink4a-Arf is also a frequent event between p16INK4a and IGFBP2 expression was also observed in in AO (3, 15). This locus encodes the p16INK4a and p14ARF human glioma tissue samples and in 90 different cancer cell lines (p19ARF in mouse) tumor-suppressor proteins, which function as CELL BIOLOGY by using Western blotting and reverse-phase protein lysate arrays. critical regulators of the RB and p53 pathways (16). Loss of When endogenous IGFBP2 expression was attenuated by an RCAS Ink4a-Arf in a mouse model of PDGFB-initiated gliomas led to vector expressing antisense IGFBP2 in our mouse model, a de- an increase in tumor incidence compared with wild-type (17). creased incidence of anaplastic oligodendroglioma as well as Additionally, loss of Ink4a-Arf was found to cooperate with K-ras prolonged survival was observed. Thus, p16INK4a is a negative to induce GBM (18). In the present study, we examined whether regulator of the IGFBP2 oncogene. Loss of Ink4a-Arf results in loss of Ink4a-Arf is directly correlated with increased IGFBP2 increased IGFBP2, which contributes to glioma progression, expression in gliomas, and we functionally interrogated the thereby implicating IGFBP2 as a marker and potential therapeutic significance of Ink4a-Arf loss in IGFBP2-mediated glioma pro- target for Ink4a-Arf-deleted gliomas. gression by using the RCAS/Ntv-a mouse glioma model. We found that the expression of IGFBP2 was inversely liomas are the most common type of human primary brain correlated with both p16INK4a and ARF expression, as well as Gtumor. Surgical resection followed by radiation therapy with PTEN, in 90 different human cancer cell lines. We then (RT) and chemotherapy has been the most common treatment examined the relationship between Ink4a-Arf deletion and IG- regimen. In patients with anaplastic oligodendroglioma (AO), FBP2 expression in an RCAS/Ntv-a glial-specific mouse model. the standard historical treatment was surgery followed by RT, Transgenic mice expressing the avian virus receptor, tv-a, under with chemotherapy being reserved for recurrence (1). Despite the control of the Nestin promoter, which drives expression in treatment, overall survival for patients with AO is 3 to 5 years, glial progenitors, were crossed to Ink4a-Arf-null mice to generate Ϫ Ϫ whereas patients with the highest grade of glioma, glioblastoma the Ntv-a; Ink4a/ARF / mice. Somatic cell gene transfer with (GBM), have a survival rate of less than 1 year (1, 2). Genetic replication-competent avian leukemia virus with splice acceptor signatures have been useful for predicting prognosis and re- (RCAS) vectors allowed the specific delivery of oncogenes to the sponse to therapy. Chromosomal aberrations, especially code- glial progenitors of these mice (19). Consistent with the human letion of 1p and 19q in AO, have been associated with both data, we observed increased mouse IGFBP2 in glial progenitor chemotherapeutic response and increased overall and progres- cells from Ink4a/ARFϪ/Ϫ, Ink4aϪ/Ϫ, and ARFϪ/Ϫ mice. Delivery sion-free survival (3). The identification and characterization of and overexpression of PDGFB to the Ntv-a; Ink4a/ARFϪ/Ϫ a number of common genetic alterations in glial tumors have newborn brain led to development of AO without the cointro- incited considerable interest in the development of targeted duction of IGFBP2, which was required in the case of wild-type therapies. A number of these therapies have achieved consid- Ntv-a mice (11). Knockdown of endogenous IGFBP2 by anti- erable success in other cancers; for example, imatinib has been sense IGFBP2 reduced high-grade glioma incidence and pro- used to target the BCR-ABL fusion protein in chronic myelog- longed survival of tumor-bearing mice. These observations enous leukemia and to target KIT and PDGFR in gastrointes- tinal stromal tumors (4). Epidermal growth factor receptor (EGFR) is commonly amplified in a wide spectrum of human Author contributions: R.S., J.M.B., G.N.F., and W.Z. designed research; L.M.M., K.M.H., S.M.S., Y.W., and E.T. performed research; L.U. contributed new reagents/analytic tools; cancers, including GBM, and is another example of targeted L.M.M., K.M.H., S.M.S., E.T., L.U., G.N.F., and W.Z. analyzed data; and L.M.M., J.M.B., G.N.F., drug development (5). However, anti-EGFR treatment has not and W.Z. wrote the paper. had the anticipated success in GBM clinical trials, despite The authors declare no conflict of interest. significant benefit in other neoplastic diseases, such as colon This article is a PNAS Direct Submission. cancer (6–8). The recent progress of targeted therapy in other 1To whom correspondence may be addressed. E-mail: [email protected] or tumor types highlights the need for identification of genetic and [email protected]. molecular alterations to serve as markers for patient stratifica- This article contains supporting information online at www.pnas.org/cgi/content/full/ tion and as targets for glioma therapeutics. 0900807106/DCSupplemental. www.pnas.org͞cgi͞doi͞10.1073͞pnas.0900807106 PNAS Early Edition ͉ 1of5 Downloaded by guest on September 24, 2021 p16Ink4a/ A B WT p16Ink4a-/-ARF-/- ARF-/- p16INK4a XXXXBBBB IGFBP2 IGFBP2 Actin Actin 12345 678 9101112 13 14 15 16 17 1 0.9 21.3 18.7 38 22 29.3 26 C IGFBP2 vs. PTEN D IGFBP2 vs. p16INK4a 26.6% 27.8% 40 10 20 2.0 2.0 1.5 1.5 1.0 1.0 0.5 0.5 0.0 Fold Difference Fold Difference 0.0 27.8% 26.6% E IGFBP2 vs. p19ARF F IGFBP2 vs. IGFBP5 18.9% 10 5 3.3% 2.0 2.0 1.5 1.5 1.0 1.0 0.5 0.5 3.3% 0.0 Fold Difference 0.0 Fold Difference 16.6% Fig. 1. IGFBP2 expression is inversely related to p16INK4a expression. (A) Protein lysates from 17 human glioma samples were examined by Western blot analysis for IGFBP2 and p16INK4a protein levels. High-grade samples include grade III oligodendroglioma (lanes 4, 10, and 11) and astrocytomas (lanes 16 and 17) as well as GBM (lanes 1–3, 6–9, and 14–15). Samples 5, 12, and 13 were classified as grade II oligodendroglioma or astrocytoma and are noted in gray. (B) Western blot of Ntv-a glial progenitor cell lysates infected with empty RCAS vector (RCAS-X) or RCAS-PDGFB. IGFBP2 protein levels are elevated in cell lysates from Ink4a/ARF-deleted, Ink4a-deleted, and ARF-deleted mice. The numbers below the figure represent relative IGFBP2 levels after normalization to actin levels. (C–F) Fold difference in protein levels between IGFBP2 and PTEN (C), p16INK4a (D), p19ARF (E), and IGFBP5 (F). Protein levels in 90 cell lines were examined by protein lysate array, and fold differences were plotted. The red areas represent samples where IGFBP2 protein levels were greater than 2-fold higher than the compared protein; green areas represent samples where IGFBP2 protein levels were at least 2-fold lower. The percent of samples with greater than 2-fold differences are listed in each graph. suggest that IGFBP2 may serve as both a marker and therapeutic colorectal carcinoma, ovarian cancer, and acute lymphoblastic target for Ink4a-Arf-deleted gliomas. leukemia (20–23). To further investigate this relationship, we mined data from Results our high-throughput reverse-phase protein lysate array analysis IGFBP2 Expression Is Inversely Correlated with p16INK4a Status. (24). This work examined 90 cell lines comprising 12 tumor types, IGFBP2 is frequently up-regulated in glioma and was identified including GBM, prostate cancer, breast cancer, and sarcoma. We recently as a potential biomarker for PTEN status and PI3K/Akt compared the relative protein levels of IGFBP2 with several pathway activation in both glioma and prostate cancer (14).
Load more

Recommended publications
  • CDH12 Cadherin 12, Type 2 N-Cadherin 2 RPL5 Ribosomal
    5 6 6 5 . 4 2 1 1 1 2 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 A A A A A A A A A A A A A A A A A A A A C C C C C C C C C C C C C C C C C C C C R R R R R R R R R R R R R R R R R R R R B , B B B B B B B B B B B B B B B B B B B , 9 , , , , 4 , , 3 0 , , , , , , , , 6 2 , , 5 , 0 8 6 4 , 7 5 7 0 2 8 9 1 3 3 3 1 1 7 5 0 4 1 4 0 7 1 0 2 0 6 7 8 0 2 5 7 8 0 3 8 5 4 9 0 1 0 8 8 3 5 6 7 4 7 9 5 2 1 1 8 2 2 1 7 9 6 2 1 7 1 1 0 4 5 3 5 8 9 1 0 0 4 2 5 0 8 1 4 1 6 9 0 0 6 3 6 9 1 0 9 0 3 8 1 3 5 6 3 6 0 4 2 6 1 0 1 2 1 9 9 7 9 5 7 1 5 8 9 8 8 2 1 9 9 1 1 1 9 6 9 8 9 7 8 4 5 8 8 6 4 8 1 1 2 8 6 2 7 9 8 3 5 4 3 2 1 7 9 5 3 1 3 2 1 2 9 5 1 1 1 1 1 1 5 9 5 3 2 6 3 4 1 3 1 1 4 1 4 1 7 1 3 4 3 2 7 6 4 2 7 2 1 2 1 5 1 6 3 5 6 1 3 6 4 7 1 6 5 1 1 4 1 6 1 7 6 4 7 e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m
    [Show full text]
  • IGFBP5) Reverses Cisplatin-Resistance in Esophageal Carcinoma
    cells Article Expression of Insulin-Like Growth Factor Binding Protein-5 (IGFBP5) Reverses Cisplatin-Resistance in Esophageal Carcinoma Dessy Chan 1,†, Yuanyuan Zhou 1,†, Chung Hin Chui 1, Kim Hung Lam 1, Simon Law 2, Albert Sun-chi Chan 3, Xingshu Li 3,*, Alfred King-yin Lam 4,* and Johnny Cheuk On Tang 1,* 1 State Key Laboratory of Chemical Biology and Drug Discovery, Lo Ka Chung Centre for Natural Anti-cancer Drug Development, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China; [email protected] (D.C.); [email protected] (Y.Z.); [email protected] (C.H.C.), [email protected] (K.H.L.) 2 Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; [email protected] 3 School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China; [email protected] 4 Griffith Medical School, Griffith University, Gold Coast, QLD 4222, Australia * Correspondence: [email protected] (X.L.); A.Lam@griffith.edu.au (A.K.L.); [email protected] (J.C.O.T.); Tel.: +852-3400-8727 (J.C.O.T.) † These authors contributed equally to this work. Received: 3 September 2018; Accepted: 16 September 2018; Published: 20 September 2018 Abstract: Cisplatin (CDDP) is one of the front-line chemotherapeutic drugs used in the treatment of esophageal squamous cell carcinoma (ESCC). Occurrence of resistance to CDDP has become one of the main challenges in cancer therapy. In this study, the gene expression profile of CDDP-resistant ESCC cells was investigated and molecular approaches were explored in an attempt to reverse the CDDP resistance.
    [Show full text]
  • Contents Supplemental Table 1
    Supplementary material Open Heart SUPPLEMENTAL MATERIAL TO “EXPLORATION OF PATHOPHYSIOLOGICAL PATHWAYS FOR INCIDENT ATRIAL FIBRILLATION – THE MALMÖ PREVENTIVE PROJECT” John Molvin, Amra Jujic, Olle Melander, Manan Pareek, Lennart Råstam, Ulf Lindblad, Bledar Daka, Margrét Leósdóttir, Peter M. Nilsson, Michael H. Olsen & Martin Magnusson Contents Supplemental table 1. Unadjusted Cox regression analyses examining all 92 proteins relation to incident atrial fibrillation ................................................................................... 2-3 List of abbreviations……………………………………………………………………………………………………………4 Molvin J, et al. Open Heart 2020; 7:e001190. doi: 10.1136/openhrt-2019-001190 Supplementary material Open Heart Supplemental table 1. Unadjusted Cox regression analyses examining all 92 proteins relation to incident atrial fibrillation Protein Hazard ratio (95% confidence interval) p-value PON3 0.80 (0.72-0.89) 7.3x10-5 IGFBP2 4.47 (1.42-14-1) 0.011 PAI 1.44 (0.65-3.18) 0.371 CTSD 2.45 (1.13-5.30) 0.023 FABP4 1.27 (1.13-1.44) 8.6x10-5 CD163 5.25 (1.14-24.1) 0.033 GAL4 1.30 (1.15-1.47) 3.5x10-5 LDL-receptor 0.81 (0.39-1.69) 0.582 IL1RT2 0.75 (0.24-2.34) 0.614 t-PA 2.75 (1.21-6.27) 0.016 SELE 0.99 (0.51-1.90) 0.969 CTSZ 2.97 (1.00-8.78) 0.050 GDF15 1.41 (1.25-1.59) 9.7x10-9 CSTB 3.75 (1.58-8.92) 0.003 MPO 4.48 (1.73-11.7) 0.002 PCSK9 1.18 (0.73-1.93) 0.501 IGFBP1 2.48 (1.42-4.35) 0.001 RARRES2 64.3 (1.87-2220.8) 0.021 ITGB2 1.01 (0.31-3.29) 0.990 CCL15 3.58 (0.96-13.3) 0.057 SCGB3A2 0.97 (0.71-1.32) 0.839 CHI3L1 1.26 (1.12-1.43)
    [Show full text]
  • Insulin-Like Growth Factor Axis in Pregnancies Affected by Fetal Growth Disorders Aamod R
    Nawathe et al. Clinical Epigenetics (2016) 8:11 DOI 10.1186/s13148-016-0178-5 RESEARCH Open Access Insulin-like growth factor axis in pregnancies affected by fetal growth disorders Aamod R. Nawathe1,2, Mark Christian3, Sung Hye Kim2, Mark Johnson1,2, Makrina D. Savvidou1,2 and Vasso Terzidou1,2* Abstract Background: Insulin-like growth factors 1 and 2 (IGF1 and IGF2) and their binding proteins (IGFBPs) are expressed in the placenta and known to regulate fetal growth. DNA methylation is an epigenetic mechanism which involves addition of methyl group to a cytosine base in the DNA forming a methylated cytosine-phosphate-guanine (CpG) dinucleotide which is known to silence gene expression. This silences gene expression, potentially altering the expression of IGFs and their binding proteins. This study investigates the relationship between DNA methylation of components of the IGF axis in the placenta and disorders in fetal growth. Placental samples were obtained from cord insertions immediately after delivery from appropriate, small (defined as birthweight <10th percentile for the gestation [SGA]) and macrosomic (defined as birthweight > the 90th percentile for the gestation [LGA]) neonates. Placental DNA methylation, mRNA expression and protein levels of components of the IGF axis were determined by pyrosequencing, rtPCR and Western blotting. Results: In the placenta from small for gestational age (SGA) neonates (n = 16), mRNA and protein levels of IGF1 were lower and of IGFBPs (1, 2, 3, 4 and 7) were higher (p < 0.05) compared to appropriately grown neonates (n =37).In contrast, in the placenta from large for gestational age (LGA) neonates (n = 20), mRNA and protein levels of IGF1 was not different and those of IGFBPs (1, 2, 3 and 4) were lower (p < 0.05) compared to appropriately grown neonates.
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • (Igfbp5) Compromises Survival, Growth, Muscle Development, and Fertility in Mice
    Insulin-like growth factor-binding protein 5 (Igfbp5) compromises survival, growth, muscle development, and fertility in mice Dervis A. M. Salih*, Gyanendra Tripathi*, Cathy Holding*, Tadge A. M. Szestak*, M. Ivelisse Gonzalez*, Emma J. Carter*, Laura J. Cobb*, Joan E. Eisemann†, and Jennifer M. Pell*‡ *Signalling Programme, The Babraham Institute, Cambridge CB2 4AT, United Kingdom; and †Department of Animal Science, North Carolina State University, Raleigh, NC 27695 Communicated by Michael J. Berridge, The Babraham Institute, Cambridge, United Kingdom, January 23, 2004 (received for review October 3, 2003) The insulin-like growth factors (IGFs) are essential for development; include a consensus nuclear localization signal (17) and serine͞ bioavailable IGF is tightly regulated by six related IGF-binding pro- threonine phosphorylation sites. These primary motifs are con- teins (IGFBPs). Igfbp5 is the most conserved and is developmentally served, signifying that putative IGF-dependent and -independent up-regulated in key lineages and pathologies; in vitro studies suggest functions have been maintained. that IGFBP-5 functions independently of IGF interaction. Genetic We have therefore pursued the hypothesis that IGFBP-5 has a ablation of individual Igfbps has yielded limited phenotypes because significant role in growth and development. IGFBP function has of substantial compensation by remaining family members. There- been investigated in vivo by using gene ablation by homologous fore, to reveal Igfbp5 actions in vivo, we generated lines of transgenic recombination (e.g., ref. 18); however, to date Igfbp-null mice have mice that ubiquitously overexpressed Igfbp5 from early develop- exhibited a limited phenotype because of compensation and re- ment. Significantly increased neonatal mortality, reduced female dundancy from remaining IGFBPs.
    [Show full text]
  • IGFBP2 Is a Biomarker for Predicting Longitudinal Deterioration in Renal Function in Type 2 Diabetes
    R P Narayanan et al. IGFBP2 predicts renal function in 1–8 1:95 Research diabetes Open Access IGFBP2 is a biomarker for predicting longitudinal deterioration in renal function in type 2 diabetes Correspondence 1 2 1 1 1 Ram P Narayanan ,BoFu , Adrian H Heald , Kirk W Siddals , Robert L Oliver , should be addressed to Julie E Hudson1, Antony Payton3, Simon G Anderson4, Anne White5, R P Narayanan 3,6 1,7 B-202, Clinical Sciences William E R Ollier and J Martin Gibson Building, Salford Royal NHS 1Vascular Research Group 2School of Community Based Medicine 3Centre for Integrated Genomic Medical Research Foundation Trust, Stott Lane, Salford 4Cardiovascular Research Group 5Endocrinology and Diabetes, Faculty of Medical, Human and Life Sciences, M6 8HD, UK The University of Manchester, Manchester M13 9PT, UK 6Salford R&D 7Department of Endocrinology and Email Diabetes, Salford Royal Hospital NHS Foundation Trust, Salford M6 8HD, UK ram.narayanan@manchester. ac.uk Abstract Objective: Insulin-like growth factors are implicated in the development of diabetic nephropathy. Key Words IGF-binding protein 2 (IGFBP2) and IGF2 are expressed in the kidney, but their associations with " IGFBP2 diabetic nephropathy are unclear. We therefore tested the hypothesis that circulating levels of " longitudinal trends IGF2 and IGFBP2 predict longitudinal renal function in individuals with type 2 diabetes. " renal function Design and methods: IGFBP2 and IGF2 measurements were performed in 436 individuals (263 " real-world data males) with type 2 diabetes. Linear mixed-effect regression analysis was used to model the Endocrine Connections relationship between plasma IGFBP2 concentration and longitudinal changes in estimated glomerular filtration rate (eGFR) over an 8-year period.
    [Show full text]
  • Protease-Resistant Form of Insulin-Like Growth Factor-Binding Protein 5 Is An
    Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture. Y Imai, … , C Rees, D R Clemmons J Clin Invest. 1997;100(10):2596-2605. https://doi.org/10.1172/JCI119803. Research Article IGFs are pleiotrophic mitogens for porcine smooth muscle cells (pSMC) in culture. The effects of IGFs on cells are modulated by various insulin-like growth factor-binding proteins (IGFBP). IGFBP-5 is synthesized by pSMC and binds to the extracellular matrix. However, IGFBP-5 is also secreted into conditioned medium of cultured cells and is cleaved into fragments by a concomitantly produced protease. These fragments have reduced affinity for the IGFs and cleavage makes it difficult to assess the role of intact IGFBP-5. To study the consequence of accumulation of intact IGFBP-5 in medium, we determined the cleavage site in IGFBP-5 and prepared a protease resistant mutant. Amino acid sequencing of purified IGFBP-5 fragments suggested Arg138-Arg139 as the primary cleavage site. Arg138-Arg139-->Asn138-Asn139 mutations were introduced to create protease-resistant IGFBP-5, which has the same affinity for IGF-I as the native protein. This mutant IGFBP-5 remained intact even after 24 h of incubation and it inhibited several IGF-I actions when added to pSMC culture medium. The mutant IGFBP-5 (500 ng/ml) decreased IGF-I stimulated cellular DNA synthesis by 84%, protein synthesis by 77%, and it inhibited IGF-I stimulated migration of pSMC by 77%. It also inhibited IGF-I stimulation of IRS-1 phosphorylation.
    [Show full text]
  • Figure S1. Reverse Transcription‑Quantitative PCR Analysis of ETV5 Mrna Expression Levels in Parental and ETV5 Stable Transfectants
    Figure S1. Reverse transcription‑quantitative PCR analysis of ETV5 mRNA expression levels in parental and ETV5 stable transfectants. (A) Hec1a and Hec1a‑ETV5 EC cell lines; (B) Ishikawa and Ishikawa‑ETV5 EC cell lines. **P<0.005, unpaired Student's t‑test. EC, endometrial cancer; ETV5, ETS variant transcription factor 5. Figure S2. Survival analysis of sample clusters 1‑4. Kaplan Meier graphs for (A) recurrence‑free and (B) overall survival. Survival curves were constructed using the Kaplan‑Meier method, and differences between sample cluster curves were analyzed by log‑rank test. Figure S3. ROC analysis of hub genes. For each gene, ROC curve (left) and mRNA expression levels (right) in control (n=35) and tumor (n=545) samples from The Cancer Genome Atlas Uterine Corpus Endometrioid Cancer cohort are shown. mRNA levels are expressed as Log2(x+1), where ‘x’ is the RSEM normalized expression value. ROC, receiver operating characteristic. Table SI. Clinicopathological characteristics of the GSE17025 dataset. Characteristic n % Atrophic endometrium 12 (postmenopausal) (Control group) Tumor stage I 91 100 Histology Endometrioid adenocarcinoma 79 86.81 Papillary serous 12 13.19 Histological grade Grade 1 30 32.97 Grade 2 36 39.56 Grade 3 25 27.47 Myometrial invasiona Superficial (<50%) 67 74.44 Deep (>50%) 23 25.56 aMyometrial invasion information was available for 90 of 91 tumor samples. Table SII. Clinicopathological characteristics of The Cancer Genome Atlas Uterine Corpus Endometrioid Cancer dataset. Characteristic n % Solid tissue normal 16 Tumor samples Stagea I 226 68.278 II 19 5.740 III 70 21.148 IV 16 4.834 Histology Endometrioid 271 81.381 Mixed 10 3.003 Serous 52 15.616 Histological grade Grade 1 78 23.423 Grade 2 91 27.327 Grade 3 164 49.249 Molecular subtypeb POLE 17 7.328 MSI 65 28.017 CN Low 90 38.793 CN High 60 25.862 CN, copy number; MSI, microsatellite instability; POLE, DNA polymerase ε.
    [Show full text]
  • Supplementary Table 1
    Supplementary Table 1. 492 genes are unique to 0 h post-heat timepoint. The name, p-value, fold change, location and family of each gene are indicated. Genes were filtered for an absolute value log2 ration 1.5 and a significance value of p ≤ 0.05. Symbol p-value Log Gene Name Location Family Ratio ABCA13 1.87E-02 3.292 ATP-binding cassette, sub-family unknown transporter A (ABC1), member 13 ABCB1 1.93E-02 −1.819 ATP-binding cassette, sub-family Plasma transporter B (MDR/TAP), member 1 Membrane ABCC3 2.83E-02 2.016 ATP-binding cassette, sub-family Plasma transporter C (CFTR/MRP), member 3 Membrane ABHD6 7.79E-03 −2.717 abhydrolase domain containing 6 Cytoplasm enzyme ACAT1 4.10E-02 3.009 acetyl-CoA acetyltransferase 1 Cytoplasm enzyme ACBD4 2.66E-03 1.722 acyl-CoA binding domain unknown other containing 4 ACSL5 1.86E-02 −2.876 acyl-CoA synthetase long-chain Cytoplasm enzyme family member 5 ADAM23 3.33E-02 −3.008 ADAM metallopeptidase domain Plasma peptidase 23 Membrane ADAM29 5.58E-03 3.463 ADAM metallopeptidase domain Plasma peptidase 29 Membrane ADAMTS17 2.67E-04 3.051 ADAM metallopeptidase with Extracellular other thrombospondin type 1 motif, 17 Space ADCYAP1R1 1.20E-02 1.848 adenylate cyclase activating Plasma G-protein polypeptide 1 (pituitary) receptor Membrane coupled type I receptor ADH6 (includes 4.02E-02 −1.845 alcohol dehydrogenase 6 (class Cytoplasm enzyme EG:130) V) AHSA2 1.54E-04 −1.6 AHA1, activator of heat shock unknown other 90kDa protein ATPase homolog 2 (yeast) AK5 3.32E-02 1.658 adenylate kinase 5 Cytoplasm kinase AK7
    [Show full text]
  • SUPPLEMENTAL INFORMATION for LKB1 Loss Promotes Endometrial Cancer Progression Via CCL2-Dependent Recruitment of Macrophages
    SUPPLEMENTAL INFORMATION FOR LKB1 loss promotes endometrial cancer progression via CCL2‐dependent recruitment of macrophages Christopher G. Peña, Yuji Nakada, Hatice D. Saatcioglu, Gina M. Aloisio, Ileana Cuevas, Song Zhang, David S. Miller, Jayanthi S. Lea, Kwok‐Kin Wong, Ralph J. DeBerardinis, Anthony L. Amelio, Rolf A. Brekken, and Diego H. Castrillon Figures S1‐6, Tables S2‐S3, and Legends 1 Figure S1. LKB1 knockdown does not affect growth rate or migration of EM cells. A) Growth curve of isogenic EM cells over an 8 day period. Values were obtained by calculating mean intensity of crystal violet staining per day normalized to day 0. B) Wound healing assay showing width of wound (µm) over time. Error bars=S.E.M. 2 Figure S2. Macrophage infiltration distinguishes Lkb1‐based from other murine endometrial cancer models. A) Representative F4/80 immunostaining of four murine endometrial cancer models showing greatest macrophage density in 12 week Lkb1‐/‐ tumors, with H&E stains showing invasive tumor for each model. B) Fold change in F4/80+ cells between each cancer model and respective sibling controls (n=4 per experimental group and sibling controls for every model analyzed). Lkb1‐/‐ mice displayed the greatest fold change in macrophage density (*P<0.01) per student’s t test. Bars=50 µm; panels in the same column are all at the same magnification. Error bars=S.E.M. 3 Figure S3. Quantitation of leukocyte infiltrates in Lkb1‐/‐ tumors. A) Immunostaining of tumors with mature lymphocyte marker CD3, neutrophil marker myeloperoxidase (MYP), and macrophage marker F4/80 in 12 week‐old animals.
    [Show full text]
  • Systematic Elucidation of Neuron-Astrocyte Interaction in Models of Amyotrophic Lateral Sclerosis Using Multi-Modal Integrated Bioinformatics Workflow
    ARTICLE https://doi.org/10.1038/s41467-020-19177-y OPEN Systematic elucidation of neuron-astrocyte interaction in models of amyotrophic lateral sclerosis using multi-modal integrated bioinformatics workflow Vartika Mishra et al.# 1234567890():,; Cell-to-cell communications are critical determinants of pathophysiological phenotypes, but methodologies for their systematic elucidation are lacking. Herein, we propose an approach for the Systematic Elucidation and Assessment of Regulatory Cell-to-cell Interaction Net- works (SEARCHIN) to identify ligand-mediated interactions between distinct cellular com- partments. To test this approach, we selected a model of amyotrophic lateral sclerosis (ALS), in which astrocytes expressing mutant superoxide dismutase-1 (mutSOD1) kill wild-type motor neurons (MNs) by an unknown mechanism. Our integrative analysis that combines proteomics and regulatory network analysis infers the interaction between astrocyte-released amyloid precursor protein (APP) and death receptor-6 (DR6) on MNs as the top predicted ligand-receptor pair. The inferred deleterious role of APP and DR6 is confirmed in vitro in models of ALS. Moreover, the DR6 knockdown in MNs of transgenic mutSOD1 mice attenuates the ALS-like phenotype. Our results support the usefulness of integrative, systems biology approach to gain insights into complex neurobiological disease processes as in ALS and posit that the proposed methodology is not restricted to this biological context and could be used in a variety of other non-cell-autonomous communication
    [Show full text]